作者
Chonghua Xue,Shreyas Kowshik,Diala Lteif,Shreyas Puducheri,Varuna Jasodanand,Olivia T. Zhou,Anika Walia,Osman Berke Güney,J. Diana Zhang,Serena T. Pham,Artem Kaliaev,V. Carlota Andreu‐Arasa,Brigid Dwyer,Chad W. Farris,Honglin Hao,Sachin Kedar,Asim Mian,Daniel L. Murman,Sarah A. O’Shea,Aaron B. Paul,Saurabh Rohatgi,Marie Saint‐Hilaire,E. Alton Sartor,Bindu N. Setty,Juan E. Small,Arun Swaminathan,Olga Taraschenko,Jing Yuan,Yan Zhou,Shuhan Zhu,Cody Karjadi,Ting Fang Alvin Ang,Sarah Adel Bargal,Bryan A. Plummer,Kathleen L. Poston,Meysam Ahangaran,Rhoda Au,Vijaya B. Kolachalama
摘要
Abstract Differential diagnosis of dementia remains a challenge in neurology due to symptom overlap across etiologies, yet it is crucial for formulating early, personalized management strategies. Here, we present an AI model that harnesses a broad array of data, including demographics, individual and family medical history, medication use, neuropsychological assessments, functional evaluations, and multimodal neuroimaging, to identify the etiologies contributing to dementia in individuals. The study, drawing on 51, 269 participants across 9 independent, geographically diverse datasets, facilitated the identification of 10 distinct dementia etiologies. It aligns diagnoses with similar management strategies, ensuring robust predictions even with incomplete data. Our model achieved a micro-averaged area under the receiver operating characteristic curve (AUROC) of 0.94 in classifying individuals with normal cognition, mild cognitive impairment and dementia. Also, the micro-averaged AUROC was 0.96 in differentiating the dementia etiologies. Our model demonstrated proficiency in addressing mixed dementia cases, with a mean AUROC of 0.78 for two cooccurring pathologies. In a randomly selected subset of 100 cases, the AUROC of neurologist assessments augmented by our AI model exceeded neurologist-only evaluations by 26.25%. Furthermore, our model predictions aligned with biomarker evidence and its associations with different proteinopathies were substantiated through postmortem findings. Our framework has the potential to be integrated as a screening tool for dementia in various clinical settings and drug trials, with promising implications for person-level management.